Critical Comparison: Inari Medical (NARI) and Its Rivals

Inari Medical (NASDAQ: NARI) is one of 175 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Inari Medical to similar companies based on the strength of its profitability, institutional ownership, valuation, earnings, risk, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current recommendations for Inari Medical and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inari Medical 0 1 5 0 2.83
Inari Medical Competitors 896 3823 7041 187 2.55

Inari Medical presently has a consensus target price of $117.17, indicating a potential upside of 28.66%. As a group, “Surgical & medical instruments” companies have a potential upside of 15.00%. Given Inari Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Inari Medical is more favorable than its competitors.


This table compares Inari Medical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inari Medical 10.08% 8.69% 7.80%
Inari Medical Competitors -666.98% -91.73% -17.81%

Valuation & Earnings

This table compares Inari Medical and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Inari Medical $139.67 million $13.79 million 337.30
Inari Medical Competitors $1.18 billion $78.77 million 73.75

Inari Medical’s competitors have higher revenue and earnings than Inari Medical. Inari Medical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

48.7% of Inari Medical shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 23.2% of Inari Medical shares are owned by insiders. Comparatively, 13.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Inari Medical beats its competitors on 8 of the 12 factors compared.

Inari Medical Company Profile

Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with's FREE daily email newsletter.